Managed Healthcare Executive October 11, 2024
PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is uneven. What is needed is more data about whether these drugs can lower overall healthcare costs.
Pharmacy benefit managers (PBMs) and the trade organization for the largest of them, the Pharmaceutical Care Management Association, have assured Congress and the public that they are committed to providing coverage for the glucagon-like peptide 1 (GLP-1) receptor agonist drugs. This much-talked-about class of drugs includes semaglutide (Ozempic for diabetes and Wegovy for weight loss) and tirzepatide (Mounjaro for diabetes and Zepbound for weight loss.)
Last month at a hearing of the U.S. Senate Committee on Health, Education, Labor, and Pensions, committee chair Senator Bernie...
Today's Sponsors
Today's Sponsor